Christopher Ballas, PhD, Innovative Cellular Therapeutics, Rockville, MD, provides an overview of the ongoing landscape of cell therapy targeting solid tumors. Solid tumors are more difficult to target compared to liquid tumors due to the lack of tumor specific targets. Whilst there has been advances in immunotherapies such as tumor-infiltrating lymphocyte (TIL) therapies, their efficacy has yet to match those of ones targeting hematological malignancies. However, advances in other therapeutic classes such as checkpoint inhibitors, natural killer (NK) cells, and gamma delta (γδ) T cells may present promising cell therapies for solid tumors. This interview took place at Advanced Therapies Week 2022.
Christopher Ballas, PhD is an employee of Innovative Cellular Therapeutics.